ReviewFrontiers in oncology2016
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Review in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein andCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Trial
- Distinct transcriptomic features of tumor and stromal cells in direct contact in luminal and triple-negative breast cancers.Exploration of targeted anti-tumor therapy · 2026Article
- Expression profiling of cochlear genes uncovers sex-based cellular function in mouse cochleae.Hearing research · 2024Article
- Oncotype DX Recurrence Score in premenopausal women.Therapeutic advances in medical oncology · 2022Review
- Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.Nature communications · 2021Article
- Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours.BMC cancer · 2021Article
- Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.Breast cancer research and treatment · 2021Article
- Timing of breast cancer surgery during the menstrual cycle-is there an optimal time of the month?Oncology letters · 2020Review
- Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.Breast cancer research : BCR · 2020Article
- Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.Breast cancer research : BCR · 2020Article
- Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.Nature cancer · 2020Article
- Review
- Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk.Frontiers in oncology · 2016Review
- The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer.Technology in cancer research & treatmentReview
- Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinics are increasingly adopting gene-expression profiling to diagnose breast cancer subtype, providing an intrinsic, molecular portrait of the tumor. For example, the PAM50-based Prosigna test quantifies expression of 50 key genes to classify breast cancer subtype, and this method of classification has been demonstrated to be superior over traditional immunohistochemical methods that detect proteins, to predict risk of disease recurrence. However, these tests were largely developed and validated using breast cancer samples from postmenopausal women. Thus, the accuracy of such tests has not been explored in the context of the hormonal fluctuations in estrogen and progesterone that occur during the menstrual cycle in premenopausal women. Concordance between traditional methods of subtyping and the new tests in premenopausal women is likely to depend on the stage of the menstrual cycle at which the tissue sample is taken and the relative effect of hormones on expression of genes versus proteins. The lack of knowledge around the effect of fluctuating estrogen and progesterone on gene expression in breast cancer patients raises serious concerns for intrinsic subtyping in premenopausal women, which comprise about 25% of breast cancer diagnoses. Further research on the impact of the menstrual cycle on intrinsic breast cancer profiling is required if premenopausal women are to benefit from the new technology of intrinsic subtyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.